The FDA has issued a warning letter to India's Vista Pharmaceuticals after it found it using corroded equipment.
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.
Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.
CDMO Patheon is investing $45 million in four sites that stretch from the West Coast of the U.S. to Italy.
BASF will expand its ibuprofen API capacity with a new plant in Ludwigshafen, Germany, and expansion of a facility in Texas.
An FDA warning letter has been issued to a CMO that made belladonna-treated teething products that the agency warned may cause seizures in infants.
Just a month after FDA staff gave a ringing endorsement to Pfizer's biosimilar for Amgen's blockbuster Epogen, the agency rejected the drug.
Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.
Bristol-Myers Squibb recalled a lot of its anticoagulant Eliquis after discovery of a bottle that contained tablets that were half the prescribed dose.